This Week in Cardiology

The cost of treating high blood pressure, heart-failure readmission policies, abdominal fat, low flow/low gradient aortic stenosis and hypertensive disorders of pregnancy are discussed this week.

Dr John Mandrola discusses upcoding for PCI, hypertension, a pacing lead issue, a PAD trial discovery, and an FDA warning on fluoroquinolones in this week’s podcast.

Carotid stents, more stem-cell retractions, AHA statement on statin safety, flu vaccine rules, medication errors, veterans care, and wasteful NIH research on golfing are discussed in this week’s podcast.

Measures of hospital quality, statin under- or over-use, Botox for AF, smoking cessation and translating trial evidence to clinical practice are discussed in this week’s podcast.

TAVR vs surgery for high-risk aortic stenosis, conflicts of interest for physicians and societies, spin in the CV literature, and low-carb diets are discussed in this week’s podcast.

The top 5 studies from the recent American Heart Association meeting and the new cholesterol guidelines are discussed in this week’s podcast.

ODYSSEY PCSK9 inhibitor trial in print, new bradycardia guidelines, echocardiography, and an AHA preview are the topics discussed in this week’s podcast.

CV outcomes in patients with type 2 diabetes, canagliflozin, cardiorespiratory fitness, the value of randomized trials, and the most important paper of 2018 are reviewed in this week’s podcast.

Oxygen supplementation, PCSK9 inhibitor pricing, rapid troponin testing, cardio-oncology and joint commission accreditation are discussed in this week’s podcast.

Low-dose rivaroxaban for CAD/PAD, hypertension management in the community, research misconduct, cyber-security in cardiac devices, and bariatric surgery are discussed in this week’s podcast.